IMC Chicago
INDV icon

IMC Chicago’s Indivior Pharmaceuticals INDV Stock Holding History

IMC Chicago’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
39,900
+14,200
+55% +$515K ﹤0.01% 3270
2026
Q1 		$783K Buy
25,700
+7,500
+41% +$248K ﹤0.01% 3517
2025
Q4 		$653K Buy
+18,200
New +$556K ﹤0.01% 3301

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IMC Chicago's INDV Position: Q2 2026 in Review

IMC Chicago sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 10,723 shares — an estimated $389K sold.

IMC Chicago first reported a position in INDV in Q4 2025 and held it in 2 quarters. The position peaked at $716K in Q4 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • IMC Chicago reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 10,723 Indivior Pharmaceuticals shares in Q2 2026, an estimated $389K.
  • IMC Chicago first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • IMC Chicago's Indivior Pharmaceuticals position peaked at $716K in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.